VXRT News and Press, Vaxart Inc. From 03/21/21

There are many ways to examine a stock's potential. For biotech companies, I usually look at their pipelines, revenue prospects, and various financial metrics. But today, I'm going to look at something different: what other investors say about two particular stocks. And the best way to do t...

This continues our series on busting options myths where we explore a different way to sell options. In this article, we discuss myths around selling puts. These myths generally teach: (i) only sell puts on companies you wouldn't mind owning; (ii) selling puts requires a neutral t...

Science stocks aren't exactly Warren Buffett's usual fare for investment. Aside from the high risks involved with trying to make new medicines and technologies, many companies that work at the cutting edge of human knowledge haven't proven their value by generating revenue. So, it shouldn't...

Scientists are still uncertain as to how quickly antibody responses against COVID-19 disappear and the level of antibody-driven protection against new coronavirus strains.However, the other component of the adaptive immunity conferred by T cells is found to remain robust against newly emergin...

Vaxart (NASDAQ: VXRT) started last month on a sour note. The phase 1 trial data for its investigational coronavirus vaccine was disappointing, and its stock sank by 58% in a single trading session. The reason: Vaxart's candidate lacked one quality considered key for a successful vac...

Vaxart 's (NASDAQ: VXRT) shares plunged 58% in one trading session after one point in a clinical trial of its coronavirus vaccine candidate disappointed investors. In this Motley Fool Live video recorded on Feb. 26, 2021 , healthcare and cannabis bureau chief Corinne Cardina and...

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C. Wainwri...

In a conference call yesterday after the closing bell, Vaxart, Inc. (VXRT) CEO Andrei Floroiu addressed concerns regarding VXA-CoV2-1, its oral COVID-19 tablet vaccine candidate.In February, the company released disappointing preliminary results from its Phase 1 study of the vaccine that...

Vaxart (NASDAQ: VXRT) made some investors quite wealthy in 2020. Its shares skyrocketed more than 1,500% on increasing enthusiasm about its tablet COVID-19 vaccine program. That momentum carried over into this year, with Vaxart stock more than quadrupling year to date by early Febru...

Vaxart (VXRT): Q4 GAAP EPS of -$0.13 misses by $0.07.Revenue of $0.36M (-90.8% Y/Y) misses by $3.99M.Cash and cash equivalents of $126.9 million as of December 31, 2020Press Release For further details see: Vaxart EPS misses by $0.07, misses on revenue